Tracon Pharmaceuticals Scraps Development of Sarcoma Drug, Seeks to Explore Strategic Alternatives

Dow Jones07-01

By Michael Susin

Tracon Pharmaceuticals is exploring near-term strategic alternatives for the business and will terminate the development of its sarcoma treatment after it failed to achieve its main goals in a trial.

The company said on Monday that the Envasarc study of envafolimab showed an objective response rate of 5% of its enrolled patients, below the primary endpoint of 11% needed to support a biologics license application.

As a result, the company is terminating further development of envafolimab and is focusing on exploring strategic alternatives that may include merger, reverse merger, acquisition, other business combination, sales of assets, licensing or other strategic transactions.

Tracon expects to reduce cash burn and to leverage its in-house product development platform in pursuing strategic alternatives.

However, Tracon added that there can be no assurance the exploration of strategic alternatives will result in any agreements or transactions.

Envafolimab treatment was designed for patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

July 01, 2024 09:40 ET (13:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2448918095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-01 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2448918095","market":"nz","top_or_hot":-1,"title":"Tracon Pharmaceuticals Scraps Development of Sarcoma Drug, Seeks to Explore Strategic Alternatives","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Michael Susin \n</p>\n<pre>\n \n</pre>\n<p>\n  Tracon Pharmaceuticals is exploring near-term strategic alternatives for the business and will terminate the development of its sarcoma treatment after it failed to achieve its main goals in a trial. \n</p>\n<p>\n  The company said on Monday that the Envasarc study of envafolimab showed an objective response rate of 5% of its enrolled patients, below the primary endpoint of 11% needed to support a biologics license application. \n</p>\n<p>\n  As a result, the company is terminating further development of envafolimab and is focusing on exploring strategic alternatives that may include merger, reverse merger, acquisition, other business combination, sales of assets, licensing or other strategic transactions. \n</p>\n<p>\n  Tracon expects to reduce cash burn and to leverage its in-house product development platform  in pursuing strategic alternatives. \n</p>\n<p>\n  However, Tracon added that there can be no assurance the exploration of strategic alternatives will result in any agreements or transactions. \n</p>\n<p>\n  Envafolimab treatment was designed for patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Michael Susin at michael.susin@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 01, 2024 09:40 ET (13:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tracon Pharmaceuticals Scraps Development of Sarcoma Drug, Seeks to Explore Strategic Alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTracon Pharmaceuticals Scraps Development of Sarcoma Drug, Seeks to Explore Strategic Alternatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-01 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Michael Susin \n\n\n \n\n\n  Tracon Pharmaceuticals is exploring near-term strategic alternatives for the business and will terminate the development of its sarcoma treatment after it failed to achieve ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TCON","symbol_name":"TRACON制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2448918095","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448918095","pubTimestamp":1719841200,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Tracon Pharmaceuticals is exploring near-term strategic alternatives for the business and will terminate the development of its sarcoma treatment after it failed to achieve its main goals in a trial.The company said on Monday that the Envasarc study of envafolimab showed an objective response rate of 5% of its enrolled patients, below the primary endpoint of 11% needed to support a biologics license application.As a result, the company is terminating further development of envafolimab and is focusing on exploring strategic alternatives that may include merger, reverse merger, acquisition, other business combination, sales of assets, licensing or other strategic transactions.Tracon expects to reduce cash burn and to leverage its in-house product development platform  in pursuing strategic alternatives.However, Tracon added that there can be no assurance the exploration of strategic alternatives will result in any agreements or transactions.Envafolimab treatment was designed for patients","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"TCON":"TRACON制药"},"translate_title":"Tracon Pharmaceuticals放弃肉瘤药物的开发，寻求探索战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TCON":0.9},"content_text":"By Michael Susin \n\n\n \n\n\n  Tracon Pharmaceuticals is exploring near-term strategic alternatives for the business and will terminate the development of its sarcoma treatment after it failed to achieve its main goals in a trial. \n\n\n  The company said on Monday that the Envasarc study of envafolimab showed an objective response rate of 5% of its enrolled patients, below the primary endpoint of 11% needed to support a biologics license application. \n\n\n  As a result, the company is terminating further development of envafolimab and is focusing on exploring strategic alternatives that may include merger, reverse merger, acquisition, other business combination, sales of assets, licensing or other strategic transactions. \n\n\n  Tracon expects to reduce cash burn and to leverage its in-house product development platform  in pursuing strategic alternatives. \n\n\n  However, Tracon added that there can be no assurance the exploration of strategic alternatives will result in any agreements or transactions. \n\n\n  Envafolimab treatment was designed for patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy. \n\n\n \n\n\n  Write to Michael Susin at michael.susin@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 01, 2024 09:40 ET (13:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448918095"}